Phase II Open-Label Trial of Tarceva in Women With Metastatic, Hormone- and HER2-Negative Breast Cancer

Summary

The goal of this trial is to determine the activity of erlotinib in a rationally selected population of women with ER-negative, PR-negative, HER2/neu-negative, EGFR-positive breast cancer. If erlotinib is shown to have activity, this could identify a form of targeted therapy for this specific subset of breast cancer patients. In addition, it may identify a subset of breast cancer patients with tumors that overexpress EGFR in whom other EGFR targeted therapies could warrant further testing.

Timeline

Start

2007-04

Primary completion

2011-04

Completion

2011-04

Outcome

Outcome not reported

Stopped (Enrollment): “not enough patients enrolled”

Publications

• Results J Clin Oncol 29, 2011 (suppl 27; abstr 296)

Drugs

Indications